NCT04906200

Brief Summary

This clinical trial compares a web-based patient-reported symptom monitoring and self management portal, the Young, Empowered \& Strong (YES), to standard therapy in managing symptoms in adolescent and young adult breast cancer survivors. YES is a web-based portal (website) to help monitor issues or symptoms women with breast cancer may experience. The YES portal may improve the quality of life of young breast cancer survivors. The YES portal may help manage symptoms and provide useful information/resources.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for not_applicable

Timeline
8mo left

Started Jun 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

3 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress88%
Jun 2021Dec 2026

First Submitted

Initial submission to the registry

May 13, 2021

Completed
15 days until next milestone

First Posted

Study publicly available on registry

May 28, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

June 28, 2021

Completed
5.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

February 19, 2026

Status Verified

February 1, 2026

Enrollment Period

5.5 years

First QC Date

May 13, 2021

Last Update Submit

February 16, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Efficacy of the Young, Empowered & Strong (YES) intervention in improving quality of life (QOL)

    Will determine the efficacy of the YES intervention compared to usual care in improving QOL, as measured by the Quality of Life in Adult Cancer Survivors Scale at 6-months (primary outcome). The QLACS contains 47 items scored on a 1 (never) to 7 (always) scale. The 47 items are grouped into 12 domains (7 generic and 5 cancer-specific). A QLACS generic summary score is calculated by adding the 7 constituent domain scores, so that a lower score (range: 31-143) corresponds to higher QOL. A QLACS cancer-specific summary score (range: 16-99) is calculated by adding the constituent domain scores of all but the "benefits" domain. The benefits domain is scored separately (range: 4-28).

    Up to 6 months

Secondary Outcomes (3)

  • Efficacy of the YES intervention in reducing specific adolescent and young adult (AYA) breast confident (BC) concerns and symptoms at 6-months compared to baseline.

    Up to 6 months

  • Sustainability of the effects of YES on AYA concerns and symptoms

    Up to 9 months post-baseline, after the completion of the 6-month active intervention period

  • Quality of Life (QOL)

    Up to 9 months

Other Outcomes (1)

  • Potential effects of the intervention on inflammatory and other biomarkers and genetic profiles

    Baseline and 6 months

Study Arms (2)

Group A (YES portal)

EXPERIMENTAL

Patients receive access to YES portal for 9 months. Patients also complete surveys at baseline and 3, 6, and 9 months.

Other: Internet-Based InterventionOther: Survey Administration

Group B (usual care)

ACTIVE COMPARATOR

Patients receive usual care for 9 months. Patients also complete surveys at baseline and 3, 6, and 9 months. After 9 months, patients may also receive access to YES portal for 3 months.

Other: Best PracticeOther: Survey Administration

Interventions

Receive usual care

Also known as: standard of care, standard therapy
Group B (usual care)

Receive access to YES portal

Group A (YES portal)

Complete survey

Group A (YES portal)Group B (usual care)

Eligibility Criteria

Age15 Years - 39 Years
Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Female
  • Age 15-39 years at diagnosis of a stage 0-III breast cancer
  • Within 3 years of breast cancer diagnosis
  • No known evidence of breast cancer recurrence (local or distant) or second primary breast cancer
  • No prior history of new other malignancy since their breast cancer diagnosis (other than non-melanoma skin cancer)
  • Able to speak, understand and read English
  • Cognitively able to complete the study requirements
  • Ability to access medical records from treating hospital
  • Willing to provide cell phone number and/or email address, and willing to receive email and/or text messages from the study team either with their own smartphone or one provided by the study team if they do not have their own to use
  • Pregnant survivors are also eligible for this protocol, given that fertility and pregnancy are important AYA issues

You may not qualify if:

  • Individuals under age 15 or over age 42
  • Stage IV or metastatic breast cancer
  • Males with breast cancer are not being recruited to this protocol. In the AYA age group, only a miniscule proportion of breast cancers occur in males. For this reason, the YES portal intervention materials have been targeted for young women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States

Location

Columbia University Medical Center

New York, New York, 10032, United States

Location

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

Location

Related Publications (1)

  • Dibble KE, Rosenberg SM, Snow C, Kirkner GJ, Tayob N, Contreras M, Roma ND, DeGraffinreid CR, Nolan TS, Hershman DL, Naughton M, Partridge AH. Young, Empowered & strong (YES): a study protocol paper for a randomized controlled trial of an mHealth symptom monitoring and self-management intervention for adolescent and young adult (AYA) breast cancer survivors. BMC Public Health. 2025 Jan 11;25(1):126. doi: 10.1186/s12889-025-21288-4.

    PMID: 39799291BACKGROUND

Related Links

MeSH Terms

Conditions

Breast Carcinoma In Situ

Interventions

Practice Guidelines as TopicStandard of Care

Condition Hierarchy (Ancestors)

Carcinoma in SituCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsBreast NeoplasmsNeoplasms by SiteBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Guidelines as TopicQuality Assurance, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and EvaluationQuality Indicators, Health Care

Study Officials

  • Michelle Naughton, PhD

    Ohio State University Comprehensive Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 13, 2021

First Posted

May 28, 2021

Study Start

June 28, 2021

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

February 19, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations